Global Retirement Partners LLC Buys New Shares in Genelux Corporation $GNLX

Global Retirement Partners LLC purchased a new stake in shares of Genelux Corporation (NASDAQ:GNLX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 227,854 shares of the company’s stock, valued at approximately $686,000.

Other large investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its position in shares of Genelux by 451.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 183,807 shares of the company’s stock worth $801,000 after acquiring an additional 150,463 shares in the last quarter. 683 Capital Management LLC bought a new stake in shares of Genelux during the 4th quarter valued at about $572,000. Marshall Wace LLP boosted its position in shares of Genelux by 312.3% during the 4th quarter. Marshall Wace LLP now owns 139,148 shares of the company’s stock valued at $607,000 after purchasing an additional 105,402 shares in the last quarter. Millennium Management LLC acquired a new stake in Genelux during the fourth quarter worth approximately $455,000. Finally, Osaic Holdings Inc. grew its stake in Genelux by 1,911.4% during the second quarter. Osaic Holdings Inc. now owns 105,016 shares of the company’s stock worth $301,000 after purchasing an additional 99,795 shares during the period. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Genelux

In other Genelux news, Director John Thomas sold 10,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $2.98, for a total value of $29,800.00. Following the transaction, the director owned 472,784 shares in the company, valued at approximately $1,408,896.32. This represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John W. Smither sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $2.91, for a total value of $34,920.00. Following the completion of the sale, the director directly owned 91,403 shares of the company’s stock, valued at $265,982.73. This trade represents a 11.61% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 25,868 shares of company stock worth $76,120. Corporate insiders own 7.50% of the company’s stock.

Genelux Trading Down 3.7%

Shares of NASDAQ GNLX opened at $2.60 on Wednesday. The firm has a market capitalization of $116.58 million, a P/E ratio of -3.02 and a beta of 0.60. The firm’s 50-day moving average price is $2.88 and its 200-day moving average price is $2.77. Genelux Corporation has a 1-year low of $2.29 and a 1-year high of $8.53.

Genelux (NASDAQ:GNLX) last issued its earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Equities research analysts forecast that Genelux Corporation will post -0.8 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Wall Street Zen downgraded Genelux from a “sell” rating to a “strong sell” rating in a report on Saturday. Benchmark reaffirmed a “speculative buy” rating on shares of Genelux in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.